Literature DB >> 21200020

N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene.

Fu-Sheng Chou1, Mark Wunderlich, Andrea Griesinger, James C Mulloy.   

Abstract

AML1-ETO (AE) is a fusion product of t(8;21) observed in 40% French-American-British M2 type of acute myeloid leukemia (AML). Clinical data suggest that Ras mutation is a frequent cooperating event in t(8;21) AML. Whether constitutively active Ras promotes leukemogenesis on the t(8;21) background has not been demonstrated experimentally. Here, we retrovirally expressed N-Ras(G12D) in AE-expressing human hematopoietic cells to investigate cooperativity. The AE/N-Ras(G12D) cultures were cytokine-independent, enriched for CD34 positivity, and possessed increased colony-forming and replating abilities. N-Ras(G12D) expression led to Bcl-2 up-regulation and reduced apoptosis. Ectopic Bcl-2 expression also resulted in enhanced colony-forming and replating abilities but was insufficient to sustain cytokine independence. AE/N-Ras(G12D) cells were more sensitive to Bcl-2 inhibition with ABT-737 than parent AE cells. Enhanced engraftment of AE/N-Ras(G12D) cells was observed on intrafemoral injection into immunodeficient mice, presumably because of improved survival in the bone marrow microenvironment. N-Ras(G12D) promotes progression toward transformation in AE-expressing cells, partially through up-regulating Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21200020      PMCID: PMC3062331          DOI: 10.1182/blood-2010-01-264119

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.

Authors:  T Okuda; Z Cai; S Yang; N Lenny; C J Lyu; J M van Deursen; H Harada; J R Downing
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

2.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

3.  Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.

Authors:  D A Yergeau; C J Hetherington; Q Wang; P Zhang; A H Sharpe; M Binder; M Marín-Padilla; D G Tenen; N A Speck; D E Zhang
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

4.  The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.

Authors:  H G Ahuja; A Foti; M Bar-Eli; M J Cline
Journal:  Blood       Date:  1990-04-15       Impact factor: 22.113

5.  The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.

Authors:  Christina Schessl; Vijay P S Rawat; Monica Cusan; Aniruddha Deshpande; Tobias M Kohl; Patricia M Rosten; Karsten Spiekermann; R Keith Humphries; Susanne Schnittger; Wolfgang Kern; Wolfgang Hiddemann; Leticia Quintanilla-Martinez; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske
Journal:  J Clin Invest       Date:  2005-07-14       Impact factor: 14.808

6.  Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci.

Authors:  C R Bartram; W D Ludwig; W Hiddemann; J Lyons; M Buschle; J Ritter; J Harbott; A Fröhlich; J W Janssen
Journal:  Leukemia       Date:  1989-04       Impact factor: 11.528

7.  AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation.

Authors:  Jörg Bäsecke; Maike Schwieger; Frank Griesinger; Bernd Schiedlmeier; Gerald Wulf; Lorenz Trümper; Carol Stocking
Journal:  Leuk Lymphoma       Date:  2005-02

8.  Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice.

Authors:  K L MacKenzie; A Dolnikov; M Millington; Y Shounan; G Symonds
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

9.  Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouse.

Authors:  Sylvie W Shen; Alla Dolnikov; Toby Passioura; Michelle Millington; Simon Wotherspoon; Alison Rice; Karen L MacKenzie; Geoff Symonds
Journal:  Exp Hematol       Date:  2004-09       Impact factor: 3.084

10.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Authors:  C J Farr; R K Saiki; H A Erlich; F McCormick; C J Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

View more
  20 in total

1.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

Review 2.  AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Authors:  Megan A Hatlen; Lan Wang; Stephen D Nimer
Journal:  Front Med       Date:  2012-08-09       Impact factor: 4.592

Review 3.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

4.  Standing at odds: mutated RAS and hematopoietic stem cells.

Authors:  Monica Nafria; Constanze Bonifer
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

Review 5.  Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.

Authors:  Susumu Goyama; James C Mulloy
Journal:  Int J Hematol       Date:  2011-05-03       Impact factor: 2.490

Review 6.  Mouse models for core binding factor leukemia.

Authors:  D W L Chin; N Watanabe-Okochi; C Q Wang; V Tergaonkar; M Osato
Journal:  Leukemia       Date:  2015-07-13       Impact factor: 11.528

7.  Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.

Authors:  Shinobu Matsuura; Ming Yan; Miao-Chia Lo; Eun-Young Ahn; Stephanie Weng; David Dangoor; Mahan Matin; Tsunehito Higashi; Gen-Sheng Feng; Dong-Er Zhang
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

8.  NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.

Authors:  Liting Xue; John A Pulikkan; Peter J M Valk; Lucio H Castilla
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

9.  UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.

Authors:  S Goyama; J Schibler; A Gasilina; M Shrestha; S Lin; K A Link; J Chen; S P Whitman; C D Bloomfield; D Nicolet; S A Assi; A Ptasinska; O Heidenreich; C Bonifer; T Kitamura; N N Nassar; J C Mulloy
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

Review 10.  Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.

Authors:  Pankit Vachhani; Prithviraj Bose; Mohamed Rahmani; Steven Grant
Journal:  Physiol Genomics       Date:  2014-05-13       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.